scholarly journals Overexpression of the Proteasome Subunits LMP2, LMP7, and MECL-1, But Not PA28α/β, Enhances the Presentation of an Immunodominant Lymphocytic Choriomeningitis Virus T Cell Epitope

2000 ◽  
Vol 165 (2) ◽  
pp. 768-778 ◽  
Author(s):  
Katrin Schwarz ◽  
Maries van den Broek ◽  
Susanne Kostka ◽  
Regine Kraft ◽  
Andrea Soza ◽  
...  
2004 ◽  
Vol 173 (6) ◽  
pp. 3925-3934 ◽  
Author(s):  
Michael Basler ◽  
Nikolay Youhnovski ◽  
Maries van den Broek ◽  
Michael Przybylski ◽  
Marcus Groettrup

1999 ◽  
Vol 73 (4) ◽  
pp. 2739-2744 ◽  
Author(s):  
C. Sedlik ◽  
A. Dridi ◽  
E. Deriaud ◽  
M. F. Saron ◽  
P. Rueda ◽  
...  

ABSTRACT We previously demonstrated that chimeric porcine parvovirus-like particles (PPV:VLP) carrying heterologous epitopes, when injected intraperitoneally into mice without adjuvant, activate strong CD4+ and CD8+ T-cell responses specific for the foreign epitopes. In the present study, we investigated the immunogenicity of PPV:VLP carrying a CD8+ T-cell epitope from the lymphocytic choriomeningitis virus (LCMV) administered by mucosal routes. Mice immunized intranasally with recombinant PPV:VLP, in the absence of adjuvant, developed high levels of PPV-specific immunoglobulin G (IgG) and/or IgA in their serum, as well as in mucosal sites such as the bronchoalveolar and intestinal fluids. Antibodies in sera from mice immunized parenterally or intranasally with PPV:VLP were strongly neutralizing in vitro. Intranasal immunization with PPV:VLP carrying the LCMV CD8+ T-cell epitope also elicited a strong peptide-specific cytotoxic-T-cell (CTL) response. In contrast, mice orally immunized with recombinant PPV:VLP did not develop any antibody or CTL responses. We also showed that mice primed with PPV:VLP are still able to develop strong CTL responses after subsequent immunization with chimeric PPV:VLP carrying a foreign CD8+T-cell epitope. These results highlight the attractive potential of PPV:VLP as a safe, nonreplicating antigen carrier to stimulate systemic and mucosal immunity after nasal administration.


2018 ◽  
Vol 56 (01) ◽  
pp. E2-E89
Author(s):  
J Brinkmann ◽  
T Schwarz ◽  
H Kefalakes ◽  
J Schulze zur Wiesch ◽  
A Kraft ◽  
...  

2020 ◽  
Author(s):  
B Csernalabics ◽  
M Smits ◽  
K Zoldan ◽  
M Panning ◽  
C Neumann-Haefelin ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document